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Global shortages of BCG 
vaccine and tuberculous 
meningitis in children
The WHO estimates that 1 million 
children younger than 15 years 
developed tuberculosis globally in 2016, 
58 000 of whom live in South Africa.1 
Vaccination with bacille Calmette-
Guerín (BCG) has been an integral part of 
childhood immunisation programmes 
in countries with a high burden of 
tuberculosis for several decades. BCG 
traditionally has been considered to 
have limited efficacy in preventing 
tuberculosis disease in adults. However, 
BCG has consistently been shown 
to protect young children against 
miliary tuberculosis and tuberculous 
meningitis2,3—a deva stating disease 
with high morbidity and mortality. Life-
long disability is common in survivors,4 
resulting in substantial social, physical, 
and economic burden to children, 
families, and health services. WHO 
strongly recommends BCG vaccination 
be given to all neonates in settings with 
a high tuberculosis burden.5
Due to problems with vaccine 
production and limited supplier options 
in some countries, the global availability 
and procurement of BCG has been a 
challenge since 2013.6 Concern was 
expressed in 2016 that this could 
lead to substantial increases in child 
mortality globally.7 A mathematical 
model estimated that, globally, more 
than 100 000 deaths per birth cohort 
over the first 15 years of life could result 
from interrupted BCG vaccine supply.8 
To date, there have not been any 
empirical data to document the actual 
consequences of BCG shortages. 
In the Western Cape province, 
South Africa, where BCG is routinely 
recommended at birth to all infants, 
BCG vaccine supply shortages were first 
experienced during 2015. Less than half 
the number of BCG vials were available 
for distribution in 2015 compared 
to the number of vials distributed 
annually in 2013 and 2014 (2013: 
24 540 vials; 2014: 28 100 vials; 2015: 
11 320 vials [personal communication: 
Sisanda Mtatambi, Biovac Institute]). 
Concerted efforts were made to reduce 
wastage of available stock, and the 
response of routine services resulted 
in only a 6% drop in reported BCG 
coverage (95% in 2014 to 89% in 2015 
[personal communication: Sonia Botha, 
Western Cape Department of Health]).9 
However, some of these reported BCG 
doses included catch-up vaccinations 
for infants not receiving vaccinations 
at birth, and in high-burden 
tuberculosis settings, infants can be 
at risk of tuberculosis exposure before 
vaccination if not vaccinated at birth. 
In addition, contingency planning led 
to the procurement of a different BCG 
strain in 2016 (Danish strain, Serum 
Statens Institute Denmark replaced 
by Moscow strain, Serum Institute of 
India).
The number of children admitted 
to the paediatric neurology ward at 
Western Cape’s Tygerberg Hospital, a 
large academic referral hospital, for 
diagnostic evaluation and manage-
ment of tuberculous meningitis or 
tuberculomas showed an alarming 
increase during 2017 (figure). We 
reviewed hospital discharge summaries 
for these children to extract age 
and BCG vaccination status. Ethics 
approval  was granted by Stellenbosch 
University Health Research Ethics 
Committee (numbers N11/01/006 
and N16/11/142 to Regan Solomons). 
Unfortunately, BCG vaccination status 
was not recorded for the majority. 
We used Poisson regression to model 
the count of admissions for 10 years 
and estimated a specific incidence 
rate ratio (IRR) for 2017 compared 
to the preceding 3 years (2014–16), 
Figure: Annual case load (top) and birth cohort analysis (bottom) of children admitted with 
tuberculous meningitis or tuberculomas to the paediatric neurology ward at Tygerberg Hospital, Cape 
Town, South Africa over a 10-year period
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with tuberculous meningitis in 2017 
(2·2 years) was the lowest observed 
over the past 10 years (figure), further 
supporting this hypothesis.
These data serve as a stark warning 
that neonatal BCG vaccination remains 
a crucial component of tuberculosis 
control in children. Disruptions to 
vaccine supply can have multiple 
effects on the health system delivery 
of BCG. Strategies should be put 
in place to prevent such stockouts. 
Surveillance data on tuberculous 
meningitis from other settings 
affected by BCG shortages should be 
systematically collected and reported 
to investigate whether similar trends 
have been observed elsewhere. Given 
the paucity of current tools to combat 
this devastating form of tuberculosis 
in children, we, as a global community, 
must demand that supplies and quality 
of BCG vaccine remain secure.
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assuming a stable population at risk 
for these 4 years. The number of 
admissions for tuberculous meningitis 
or tuberculomas increased from a 
mean of 32·7 in 2014–16 to 70 in 2017 
(IRR 2·2, 95% CI 1·6–2·9; p<0·0001). 
This increase cannot be explained 
by a concomitant increase in overall 
tuberculosis incidence, since the 
tuberculosis case notification rate 
in the province has been steadily 
declining since 2008 (figure; personal 
communication: Alvera Swartz, Western 
Cape Department of Health).10 There 
were also no changes in the diagnostic 
algorithm used for tuberculous 
meningitis in this clinical setting 
over the 10 years of investigation, 
no changes in clinical care or hospital 
referral pathways during 2014–17, 
and no increase in the total number 
of general and specialised paediatric 
admissions at Tygerberg Hospital 
during 2017 (15 695 in 2017 vs a mean 
of 16 727 in 2014–1611). 
We hypothesise that this sharp 
increase in the number of children with 
tuberculous meningitis is related to 
BCG shortages. To further evaluate the 
relation between BCG vaccination and 
tuberculous meningitis incidence, we 
completed birth cohort analyses. As 
surveillance data were only available 
until 2017, children were divided into 
birth cohorts by calendar year of birth 
(2008–15), with 2 years of follow-up 
time in each cohort (figure). Admissions 
for tuberculous meningitis or 
tuberculomas before the age of 2 years 
were almost three times higher in 
children born in 2015 compared to the 
mean number of those born in 2012–14 
(n=15 vs n=5·7; IRR=2·7, 95% CI 1·3–5·5; 
p=0·005). Given that the median age of 
children with tuberculous meningitis 
in a large observational cohort over 
a period of 20 years at Tygerberg 
Hospital was 2·3 years,12 it would be 
expected that the peak would occur 
just over 2 years after the actual BCG 
shortage occurred if shortages of BCG 
led to increased numbers of tuberculous 
meningitis cases. This was indeed 
the case. The median age of children 
